Financials Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 22/06/2024 am IST 5-day change 1st Jan Change
134.6 USD +0.37% Intraday chart for Neurocrine Biosciences, Inc. -0.65% +2.13%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,899 8,955 8,080 11,482 12,946 13,543 - -
Enterprise Value (EV) 1 9,279 8,472 7,704 10,363 11,397 11,543 10,732 10,399
P/E ratio 276 x 23 x 92.6 x 76.6 x 53.3 x 33.2 x 21.2 x 15.4 x
Yield - - - - - - - -
Capitalization / Revenue 12.6 x 8.56 x 7.13 x 7.71 x 6.86 x 6.1 x 5.31 x 4.56 x
EV / Revenue 11.8 x 8.1 x 6.8 x 6.96 x 6.04 x 5.2 x 4.21 x 3.5 x
EV / EBITDA 116 x 44.2 x 58.9 x 39.2 x 42.4 x 20.8 x 12.8 x 9.39 x
EV / FCF 67.6 x 38.9 x 33 x 32.1 x 31.5 x 20.9 x 14.1 x 10.9 x
FCF Yield 1.48% 2.57% 3.03% 3.12% 3.17% 4.79% 7.1% 9.17%
Price to Book 15.6 x 7.92 x 5.86 x 6.75 x 5.83 x 4.97 x 4.05 x 2.83 x
Nbr of stocks (in thousands) 92,094 93,429 94,867 96,134 98,252 1,00,637 - -
Reference price 2 107.5 95.85 85.17 119.4 131.8 134.6 134.6 134.6
Announcement Date 04/02/20 04/02/21 11/02/22 06/02/23 07/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 788.1 1,046 1,134 1,489 1,887 2,219 2,551 2,973
EBITDA 1 79.74 191.6 130.7 264.1 268.7 555.8 838.4 1,107
EBIT 1 72.3 163 102.5 249 250.9 567.7 822.9 1,134
Operating Margin 9.17% 15.58% 9.04% 16.73% 13.3% 25.58% 32.25% 38.15%
Earnings before Tax (EBT) 1 46.5 106.7 101.4 213.9 332.1 545.9 872.4 1,185
Net income 1 37 407.3 89.6 154.5 249.7 431 674.8 916.5
Net margin 4.69% 38.94% 7.9% 10.38% 13.23% 19.42% 26.45% 30.83%
EPS 2 0.3900 4.160 0.9200 1.560 2.470 4.058 6.341 8.723
Free Cash Flow 1 137.3 217.6 233.1 323 361.6 553.2 761.7 953.6
FCF margin 17.42% 20.81% 20.56% 21.7% 19.16% 24.92% 29.86% 32.08%
FCF Conversion (EBITDA) 172.2% 113.57% 178.35% 122.3% 134.56% 99.52% 90.86% 86.11%
FCF Conversion (Net income) 371.1% 53.42% 260.16% 209.06% 144.8% 128.34% 112.89% 104.05%
Dividend per Share 2 - - - - - - - -
Announcement Date 04/02/20 04/02/21 11/02/22 06/02/23 07/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 312 310.6 378.2 387.9 412 420.4 452.7 498.8 515.2 515.3 547.4 569.4 589.8 587.9 615.6
EBITDA 1 -28.9 6.8 59 91.8 107.3 -109.2 78.7 144 155.2 105.5 145.9 158.5 136.3 - -
EBIT 1 -36.3 3.1 54.7 87.8 103.4 -114.2 73.6 141.2 150.3 99.3 145.5 162.9 171.9 131 166.4
Operating Margin -11.63% 1% 14.46% 22.63% 25.1% -27.16% 16.26% 28.31% 29.17% 19.27% 26.58% 28.6% 29.14% 22.28% 27.03%
Earnings before Tax (EBT) 1 -13.8 21.4 -23.3 97.9 117.9 -103.3 121.6 115.6 198.2 34.5 139.9 177.8 185.4 142 178.4
Net income 1 -7.3 13.9 -16.9 68.5 89 -76.6 95.5 83.1 147.7 43.4 113.9 134.5 147.3 109.3 137.4
Net margin -2.34% 4.48% -4.47% 17.66% 21.6% -18.22% 21.1% 16.66% 28.67% 8.42% 20.8% 23.62% 24.97% 18.59% 22.32%
EPS 2 -0.0800 0.1400 -0.1800 0.6900 0.8800 -0.7900 0.9500 0.8200 1.440 0.4200 1.033 1.247 1.309 1.178 1.400
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/02/22 04/05/22 04/08/22 01/11/22 06/02/23 03/05/23 01/08/23 31/10/23 07/02/24 01/05/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 620 483 376 1,119 1,549 2,000 2,810 3,144
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 137 218 233 323 362 553 762 954
ROE (net income / shareholders' equity) 6.62% 46.2% 14.9% 22.3% 12.7% 24% 35.1% 23.8%
ROA (Net income/ Total Assets) 3.22% 26.8% 9.76% 15.5% 8.89% 20.8% 50.3% -
Assets 1 1,150 1,520 918 999.7 2,810 2,074 1,341 -
Book Value Per Share 2 6.900 12.10 14.50 17.70 22.60 27.10 33.20 47.60
Cash Flow per Share 2 1.590 2.340 2.620 3.430 3.860 4.840 8.850 9.120
Capex 1 14.7 10.9 23.4 16.5 28.3 21 19.3 20.5
Capex / Sales 1.87% 1.04% 2.06% 1.11% 1.5% 0.94% 0.76% 0.69%
Announcement Date 04/02/20 04/02/21 11/02/22 06/02/23 07/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
134.6 USD
Average target price
160.5 USD
Spread / Average Target
+19.30%
Consensus
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Financials Neurocrine Biosciences, Inc.